Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer

Plain-language summary

This study investigated identifying and monitoring patients with ALK-translocated non-small cell lung cancer through blood samples. People with a biopsy-verified ALK translocation and non-small cell lung cancer could take part. It was carried out as a non-phase (observational) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Aarhus

Start date

3/1/2016

Estimated completion

12/1/2018

Countries

Denmark

Related genes

Locations

• Aarhus, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Non-small cell lung cancer diagnosis
* Biopsy-verified ALK-translocation

Exclusion Criteria:

* Patients were it is not possible to retrieve a biopsy
* Patients with squamous cell carcinoma